Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 3/20 | 0.49 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28924101 | 0.98 | MEN1 (0.54) | MEN1KMT2AMAPTMAPK1MTNR1B | |
| SCHEMBL30543838 | 0.92 | KMT2A (0.63) | MEN1KMT2AMAPTMAPK1MTNR1B | |
| SCHEMBL361514 | 0.92 | KMT2A (0.63) | MEN1KMT2AMAPTMAPK1MTNR1B | |
| SCHEMBL13228861 | 0.92 | APP (0.50) | MEN1KMT2AMAPTMAPK1MTNR1B | |
| SCHEMBL28630951 | 0.91 | LTA4H (0.55) | MEN1KMT2AMAPTMAPK1MTNR1B | |
| Hydrochloric Acid SCHEMBL27686057 | 0.90 | KMT2A (0.61) | MEN1KMT2AMAPTMAPK1MTNR1B | |
| SCHEMBL18905642 | 0.90 | APP (0.51) | MEN1KMT2AMAPTMAPK1MTNR1B | |
| Hydrochloric Acid SCHEMBL28644164 | 0.89 | LTA4H (0.53) | MEN1KMT2AMAPTMAPK1MTNR1B | |
| SCHEMBL16256473 | 0.87 | MTNR1B (0.64) | MTNR1BSMN1; SMN2MTNR1APOLBPGR | |
| SCHEMBL8310971 | 0.84 | TSHR (0.52) | MEN1KMT2AMAPTMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286904-A1 | INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF | BRIDGENE BIOSCIENCES, INC. | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286904-A1 | INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF | TEAD1, TEAD2, TEAD3 | MEN1 624/4885KMT2A 825/4885MAPT 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.